The Gross Law Firm has announced an investigation into possible securities fraud involving Biogen Inc. Investors who suffered losses on Biogen stock are encouraged to contact the firm to discuss their legal rights. The firm alleges that misleading statements or omissions by Biogen may have artificially inflated the stock price, leading to investor losses. This notice aims to protect shareholders and seek compensation for those affected by the alleged fraud.
Biogen is under investigation by Pomerantz LLP for possible securities fraud following the release of Phase 2 trial results for its Alzheimer's drug candidate diranersen. Although Biogen called the results "compelling," the trial failed to meet its p...
Biogen's stock struggles to surpass its $206 resistance level despite the company's acquisition of Apellis and strong sales growth of its Alzheimer's drug Leqembi, which saw a 75% year-over-year increase to $168 million in Q1 2026. However, skepticis...
